Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from calcineurin inhibitor to Nulojix in stable kidney transplant recipients
NL-OMON47903Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belatacept in kidney transplant, sponsored by Bristol Myers Squibb. Started May 2014; status: active, not recruiting.
02
Drugs
belatacept
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON47903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47903.